Trade Summary
2 months ago, Mpm Bioventures 2018, L.P., serving as 10% owner at Aktis Oncology, Inc. (AKTS), purchased 1,112,777 shares at $18.00 per share, for a total transaction value of $20,029,986.00. Following this transaction, Mpm Bioventures 2018, L.P. now holds 10,260,064 shares of AKTS.
This purchase represents a 12.00% increase in Mpm Bioventures 2018, L.P.'s stake in the company. This is considered a high-conviction trade given the significant change in ownership.
The trade was executed on Monday, January 12, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, January 14, 2026, 2 days after the trade was made.
Aktis Oncology, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.
